Increasing adoption of XEMBIFY is part of Grifols’ broader Ig business strategy focused on treating immunodeficiencies, which represent more than half of the total Ig market and whose growth is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback